For all of your information to stay up to date with AIDS Care Ocean State and the world.

Only FDA-Approved Treatment for Relief of Noninfectious Diarrhea in HIV+ Patients Now Available
October 13, 2016

Napo Pharmaceuticals Launches Mytesi (crofelemer) as the Only FDA-Approved Treatment for Relief of Noninfectious Diarrhea in HIV+ Patients 

Launch Includes Copay Savings and Patient Assistance Programs to Ensure Affordable Access to Mytesi™, Formerly Marketed as Fulyzaq® 

October 13th 2016, today, NAPO Pharmceuticals announced the launch and general availability of the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients. Alongside this announcement NAPO also released news of their Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with affordable access to the drug.

Lisa Conte, CEO and founder of Napo, stated, "Chronic, symptomatic diarrhea remains a significant, underreported consequence of HIV, whether due to the side effects of antiretroviral therapy (ART) or the direct effect of HIV on the gastrointestinal (GI) tract. This problem is only going to increase as the HIV+ population gets older; more than 40 percent of people currently living with HIV/AIDS in the United States are over the age of 50."

The Mytesi Copay Savings Program provides copay assistance to eligible patients who have private health insurance, with the intent to have patients pay no more than $25 for a Mytesi prescription. The NapoCares Patient Assistance Program provides Mytesi free of charge to eligible patients who are not insured and may not be able to afford medication.

Click here to read the full story!


News & Events